a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CLRB warrants are cheaper to buy= leverage
Warrants like CLRBW & CLRBZ....but research and remember their EXPIRATION DATES TO AVOID LOSING 100% of your investment!!!
Qualcomm stock price target raised to $78 from $64 at Susquehanna
MARKETWATCH – 9:02 AM ET 01/17/2018
LET ME COUNT THE WAYS TO BOOST PRICE:
https://seekingalpha.com/news/3322960-qualcomm-promises-big-fy19-profits-shareholders-block-broadcom
Fear of takeover forces QCOM management to boost price
And they are pumping their own stock. It feels like the Pink Sheets!
https://www.cnbc.com/2018/01/16/nomura-upgrades-qualcomm-to-buy.html
UP, UP & AWAY
PRICE JUST KEEP GOING UP FOR QCOM.
Sunofwolf: Just think “JUNO” and then
Picture CLRB.
(READ JUNO’s buyout news about Celgene and imagine CLRB...NOT TO MENTION JUNO IS UP IN AFTERHOURS BY 42% TODAY!)
https://www.cnbc.com/2018/01/16/celgene-is-in-talks-to-buy-juno-therapeutics.html
P.S. All CLRB needs is great blood cancer news on its Phase one & two clinical trials. News updates on those trials are due this winter, right?
Hope it is good news for patients’ sake.
This stock is even MORE SPECULATIVE,
after today’s SEC filing. Right?
The contract manufacturer of FDA compliant CLRB products could could QUICKLY lever up clinical trial, and more importantly for the company, commercialized drug platform sales.
Or the outsourcing could mean CLRB is on the edge of oblivion. Think, Bluebird instead.
EITHER WAY, IT SEEMS GOOD MANAGEMENT TO BUY MORE TIME FOR CLINICAL TRIALS ON MULTIPLE CANCER TYPES AND TO BUY FASTER LIFT OFF TO HUGE PROFITS IF ONE OR MORE DRUG PLATFORMS IS SUCCESSFUL.
”...pays your money, and takes ‘yer chances...”, kids!
Up 6 +% today on no news- Merry Christmas!
Rymankoly: so true & Shorty sells every spike,
UNTIL THE REALLLY BIG MONEY BUYS IN SIZE IN ONE OR TWO YEARS UPON REALIZATION (PROOF) CLRB IS THE REAL DEAL. FOR EXAMPLE, LOOK AT THIS MORING’s SPKE SELL OFF. Could be SHORTY OR JUST FLIPPERS.
BUT LOOK AT CLRB’S competitor, “BLUEBIRD”, in our sector. It will take 3 years to capitalize, but IT is PRICED IN ABOUT THE HUNDRED DOLLAR PRICE RANGE ALREADY. OF COURSE IT HELPS TO
HAVE CELGENE BACKING YOU!
ANOTHER 18 MONTHS?
Invest do not trade....RADIO SILENCE FOR ME UNTIL CLRB BREAKS $2.25 PPS......
They sell every spike, UNTIL
THE REALLLY BIG MONEY BUYS IN SIZE UPON REALIZATION (PROOF) CLRB IS THE REAL DEAL. FOR EXAMPLE, LOOK AT THE NIBBLE OF 200,000 shares bought just after the open today on the IHUB chart just above.
ANOTHER 6 MONTHS?
Invest do not trade....RADIO SILENCE FOR ME UNTIL CLRB BREAKS $2.25 PPS......
This seals the credibility of today's PR:
12-6-17:
"...In addition to the CLR 131 infusion(s), MM patients will receive 40 mg oral dexamethasone weekly for up to 12 weeks. Efficacy responses will be determined by the latest International Multiple Myeloma Working Group criteria. Efficacy for all lymphoma patients will be determined according to Lugano criteria. Cellectar will receive approximately $2 million in a non-dilutive grant from the National Cancer Institute to help fund the trial. More information about the trial, including eligibility requirements, can be found at www.clinicaltrials.gov, reference NCT02952508."
THOSE 10% SHORTS ARE GOING TO HAVE TO COVER AFTER THEY RAKE IN YOUR MONEY A FEW MORE TIMES. THIS STOCK IS THE REAL DEAL FOR SO MANY SUFFERING TYPES OF CANCER PATIENTS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
They are the ones who count in this happy ending story.
HO HO HO....Merry Christmas
For one day....19 days early at that...HO HO HO!!!
LUMPS OF COAL???
BAGS of DIAMONDS???
CLRB COMMON SHARES & WARRANTS ARE THE PERFECT CHRISTMAS PRESENTS FOR 2019!!!!!
YES, 2019. Can you wait like Warren Buffett????
Qualcomm signs $12 bln in China deals (MOU) amid Trump visit
BY Reuters
— 10:06 PM ET 11/08/2017
And: https://ih.advfn.com/p.php?pid=nmona&article=76052127
Pre-Market now BID $65.65 QCOM after $65.75 open Pre-Market...
Interesting article mentioned in last post:
https://www.cnbc.com/2017/11/06/broadcom-makes-unsolicited-bid-for-qualcomm-in-largest-tech-deal-in-history.html
First week in December 2018 will be
a really big time period in that then AVGO (Broadcom) will have a hard deadline to launch a Proxy battle with QCOM shareholders!
Per David Faber in his article in CNBC website:
"...This time, Broadcom is determined to bring its offer to the attention of Qualcomm shareholders. People familiar with the company's thinking indicate Broadcom will not shy away from initiating a proxy fight to gain seats on Qualcomm's board of directors in support of its offer..."
https://investorshub.advfn.com/Qualcomm-Inc-QCOM-238/
Qualcomm's annual meeting is currently scheduled for March with the deadline for nominating directors sometime in December.
DECEMBER 5 or so.
jWard99: your pattern looks likely,
but you are rushing it. The Premarket is up this morning less than twenty-five cents or was when last I checked.
AVGO WILL BE IN A HURRY TO UP THE ANTI ON ITS BID AFTER QCOM REJECTS IT, BECAUSE THE DEADLINE TO NOMINATE NEW DIRECTORS FOR THE QCOM MARCH ANNUAL MEETING IS THIS MONTH- November 2017.
SO I EXPECT A PROMPT HIGHER OFFER WITHIN A WEEK. OCICBW!
Then we might be on your schedule and hit $70?What do you think?
Cramer suggested listening to Broadcom conference call
before Qualcomm trading tomorrow.
Maybe that is where they will discuss the Qualcomm price per share offer and how firm it will be.
Most stories say up to $70 per share but Reuters recent story bases on confidential sources specified $70 top $80 per share. PR or conference call tomorrow by Broadcom should clear the air!
CLRB IT WAS A PLEASURE- OUT OF IHUB,
Aouvier, we can't survive without your prompt news feed.
Good bye and good luck to alll longs, shorts and cash keepers.
Adios!
THANKS FOR THE TIP!!!
"Buy the dip"- got it!
MAKE CLRB GREAT AGAIN
Does everyone have a Seaking Alpha app?
https://seekingalpha.com/article/4110137-daily-pharma-scoop-celgenes-celmod-potential-allergans-senate-troubles-abbott-approval-surge
Mention if CLRB IN LINK?
CLRB IS CRASHING TODAY, crashing
Up!
Truth time: 9:30 am...ROFLMAO
I might...recommend doing it!
Maybe solid, good and veritable news leaking out!
DD needs to include calling investor relations at CLRB. There is no insider information available, but DD
includes some asymmetrical efforts here in Edgar, in France and with whales eying CLRB as a buyout candidate.
Ms. Pre-Market is getting bullish on CLRB
BUT ONLY ON ABOUT 15,000 shares traded.
But someone in the Pe-market thinks CLRB is more attractive than the recent posters on this IHUB Board.
((;
I am keeping all my CLRB shares and warrants based upon my review of recent developments.
Time will tell who wins and who loses here.
SIGN OF IMPENDING PRICE RALLY:
Sunofwolf sells all shares!
It always happens...Ms. Market gets her way.
Could this lead to dilution:
https://finance.yahoo.com/news/cellectar-biosciences-announces-7-76-173000742.html
Current CLRB sideshow used by CEO:
https://seekingalpha.com/article/4112131-cellectar-biosciences-clrb-presents-microcap-conference-slideshow
(For those of you who like most current.)
Page 20 is most interesting for investors, but another page shows a thee year timeline to get near sales of CLR131.
FROM TODAY's PR:
..."To date, the PDC molecules have demonstrated a clear cancer targeting advantage over the unconjugated payloads," said Jim Caruso, president and CEO of Cellectar Biosciences. "We look forward to leveraging the synergistic technologies and skills of our respective organizations to further advance this exciting research...."
Oh 'la 'la...stock has a "shrinkage" proble,
It quickly deflates after each round of conquest!
Today it enjoyed $2.00
Then it shrunk by...15 cents (;
C
It needs constant stimulation.
This must be an old man's stock!
From today's PR
"...To date, the PDC molecules have demonstrated a [color=red]clear cancer targeting advantage[color=red] over the unconjugated payloads," said Jim Caruso, president and CEO of Cellectar Biosciences. "We look forward to leveraging the synergistic technologies and skills of our respective organizations to further advance this exciting research."
Yes, $1.76...eom
Do what works best for you,
But with a relapsed case of MM, it is not hard to root for CLRB NO MATER THE MARKET CONTORTIONS.
Cheerful point you make there, Rymankoly,
but the wait, whatever it turns out to be, will be worth the wait to those of us left with MM.
ADDED SHARES AT $1.70 just now,
but this item may be why some folks are tire of waiting and selling now:
"...Cellectar Biosciences Inc (CLRB) - company intends to advance compound into a fifth cohort using a multi-dose regimen"- Source text for Eikon: ..."Further company coverage:.
BUY THE DIPS, I am,
just on the concluding paragraph of the press release, the earnings potential of CLR 131 tripled:
"...On April 27, 2017, the company reported that preclinical experiments providing multiple doses (two or three doses) of CLR 131 resulted in a statistically significant benefit in survival and tumor burden reduction compared to a single dose regimen. Therefore the company has now elected to advance with a multi-dose regimen, which may provide patients with enhanced clinical benefits and treatment outcomes."
These cohort 4 patients were in bad shape and ready to expire- CLR 131 saved them. IMHO
Cryptic...what when where why
CLR131 is the future of cancer fighting success...
Closing at $1.81 is a nice Fibonacci retracement
...From the day's high of $1.85 or 50%.
(Even with the sizable sale at 1:45pm ET ?)
Volume for the day remains minimal. There is no news leak yet.
Here are the sales potentials:
$850,000,000 per year from CLRB CORPORATE SLIDE SHOW AT PAGE 19 AS DISPLAYED AT LAST CONFERENCE!
https://seekingalpha.com/article/4106671-cellectar-biosciences-clrb-presents-rodman-and-renshaw-19th-annual-global-investment
CLRB needs more revenue from sales
than anything else.
Agreements are fine, BUT SHOW ME THE MONEY!
UP, Up, up like a real flying bird,
Such a good example of "flying"!
Go CLRB, as high as you can!